StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Ioversol

HCID 3741
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
8771-40-2
Standard-SMILES
O=C(NCC(O)CO)c1c(I)c(C(=O)NCC(O)CO)c(I)c(N(CCO)C(=O)CO)c1I
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
Summenformel
C18H24I3N3O9
Durchschnittliche Molmasse
807,1 g/mol
Monoisotopische Masse
806,8647

Überblick

Ioversol is an amidobenzoic acid.

Namen und Bezeichner

Bevorzugter Name
Ioversol
IUPAC
1-N,3-N-bis(2,3-dihydroxypropyl)-5-[(2-hydroxyacetyl)-(2-hydroxyethyl)amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
Englischer Name
Ioversol
Summenformel
C18H24I3N3O9
Molmasse
807.11

Namen und Synonyme

ioversol87771-40-2OptirayMP-328Optiray 320IoversolumOptiray 160Optiray 240Optiray 300Optiray 350DTXSID2045521MP 328
Weitere Namen anzeigen
LoversolP 530oversolIodofolIodophorolIoversol API
1,3-Benzenedicarboxamide, N,N'-bis(2,3-dihydroxypropyl)-5-((hydroxyacetyl)(2-hydroxyethyl)amino)-2,4,6-triiodo-N3RIB7X24KN,N'-Bis(2,3-dihydroxypropyl)-5-(N-(2-hydroxyethyl)glycolamido)-2,4,6-triiodoisophthalamideDTXCID0025521N1,N3-bis(2,3-dihydroxypropyl)-5-[2-hydroxy-N-(2-hydroxyethyl)acetamido]-2,4,6-triiodobenzene-1,3-dicarboxamideioversoloN1,N3-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-(2-hydroxyethyl)acetamido)-2,4,6-triiodobenzene-1,3-dicarboxamideRefChem:57669

Datenbank-Bezeichner

CAS
8771-40-2、87771-40-2
PubChem CID
3741
DTXSID
DTXSID2045521
ChEMBL
CHEMBL1200614
ChEBI
CHEBI:31717
UNII
N3RIB7X24K
EC Number
618-068-0
Nikkaji
J33.102C

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-3
Polarare Oberfläche (TPSA)
200 Ų
H-Brücken-Donoren
8
H-Brücken-Akzeptoren
9
Frei drehbare Bindungen
12
Schwere Atome
33
Formalladung
0
Komplexität
623

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals
LogP-2.98
SolubilityWater soluble
Human Drugs · 3 Einträge

Breast Feeding; Lactation; Milk, Human; Contrast Media; Diagnostic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point180-182°C
Collision Cross Section216.25 Ų [M+H]+

Physikochemische Eigenschaften

Schmelzpunkt
180 · 180-182°C
Siedepunkt
864.9 · 864.9±65.0 °C(Predicted)
Dichte
37 · d37 1.371 (c = 320 mgI/ml)
storage temp.
Refrigerator
Löslichkeit
DMSO (Sparingly), Methanol (Slightly)
pka
11.34 · 11.34±0.46(Predicted)
Aggregatzustand
Solid
Farbe
White to Off-White
Major Application
pharmaceutical
InChI
InChI=1S/C18H24I3N3O9/c19-13-11(17(32)22-3-8(29)5-26)14(20)16(24(1-2-25)10(31)7-28)15(21)12(13)18(33)23-4-9(30)6-27/h8-9,25-30H,1-7H2,(H,22,32)(H,23,33)
InChIKey
AMDBBAQNWSUWGN-UHFFFAOYSA-N
SMILES
C1(C(NCC(O)CO)=O)=C(I)C(N(C(CO)=O)CCO)=C(I)C(C(NCC(O)CO)=O)=C1I
CAS Datenbank
87771 · 87771-40-2(CAS DataBase Reference)

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Ioversol

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
hs_code
2924296000
Toxizität
LD50 in mice, rats, rabbits, dogs (gI/kg): 17, 15, >25, >12 i.v.; in male, female rats (mgI/kg): 1000, >1200 intracisternally (Ralston)
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

V08AB07

V - Various

QV - Various

Protein BindingIoversol does not bind to serum or plasma proteins.
Pharmacodynamics · 1 Eintrag

The contrast enhancement obtained with ioversol is related to iodine content. Immediately after ioversol is injected, a peak in iodine plasma levels can be detected. However, depending on the organ being imaged, the time to maximum contrast will vary. The time to maximum contrast enhancement will range from the time iodine plasma levels reach their highest concentration to one hour after intravenous bolus administration. The delay between a peak in iodine plasma levels and maximum contrast enhancement is partly due to the accumulation of iodine-containing medium within a lesion and outside the blood pool. For angiographies, the maximum contrast enhancement of ioversol occurs almost immediately (15-120 seconds). Following rapid intravenous injection, ioversol can be visualized in the renal parenchyma within 30 to 60 seconds. In patients with normal renal function, opacification of the calyces and pelves takes place within 1-3 minutes, with an optimum contrast within 5-15 minutes.

Mechanism of Action · 1 Eintrag

Ioversol is a highly soluble non-ionic ionidated contrast agent. Intravascular injection of ioversol opacifies those vessels in the path of the flow of the contrast medium, allowing the radiographic visualization of the internal structures until significant hemodilution occurs. In imaging procedures, ioversol diffuses from the vascular to the extravascular space. In brains with an intact blood-brain barrier, this agent does not diffuse to the extravascular space. However, in patients with a disrupted blood-brain barrier, ioversol accumulates in the interstitial space of the disrupted region. As the product Optiray, ioversol enhances computed tomographic imaging through augmentation of radiographic efficiency with the degree of density enhancement directly related to the iodine content in an administered dose.

Biological Half-LifeThe elimination half-life was 1.5 hr in healthy volunteers (n=12) receiving 50 and 150 mL of ioversol 68%. In patients with renal dysfunction, the elimination half-life of ioversol is prolonged.
Metabolism/MetabolitesIoversol does not undergo significant metabolism, deiodination or biotransformation.
FDA Pharmacological Classification · 6 Einträge

N3RIB7X24K

IOVERSOL

Established Pharmacologic Class [EPC] - Radiographic Contrast Agent

Mechanisms of Action [MoA] - X-Ray Contrast Activity

Ioversol is a Radiographic Contrast Agent. The mechanism of action of ioversol is as a X-Ray Contrast Activity.

IOVERSOL

MeSH Pharmacological ClassificationSubstances used to allow enhanced visualization of tissues.
Absorption, Distribution and Excretion · 4 Einträge

Healthy volunteers that received 50 and 150 mL of ioversol, had a corresponding Cmax of 1.45 mg/mL and 2.36 mg/mL and a corresponding tmax of 2.0 min and 4.3 min. AUC was 1.74 mg⋅hr/mL in healthy volunteers that received 50 mL of ioversol, and 4.43 mg⋅hr/mL in those that received 150 mL. The pharmacokinetics of ioversol follow an open two compartment model with first-order elimination. Since ioversol is almost completely excreted by the kidney as a parent drug, patients with renal impairment are expected to have a lower elimination rate.

Following intravascular administration, ioversol is excreted mainly through the kidneys. Within the first 24 hours, more than 95% of the administered dose is excreted. Urine concentration peaks in the first 2 hours after ioversol is administered. Fecal elimination is negligible.

In adults, the volume of distribution of ioversol was 0.26 L/kg body weight, consistent with its extracellular space distribution.

In healthy volunteers that received 50 mL of ioversol, clearance was 156 mL/min, and in those receiving 150 mL of ioversol, clearance was 185 mL/min.

Verwendung und Herstellung

UsesUse (kg) in Switzerland (2009): >2500
Anwendungen · 2 Einträge

VerwendenNonionic, low osmolality, radiographic contrast agent. Diagnostic aid (radiopaque medium).

VerwendenLoversol is a radiopaque contrast agent. Ioversol contains iodine, a substance that absorbs x-rays. Contrast agents are used to allow blood vessels, organs, and other non-bony tissues to be seen more clearly on a CT scan or other radiologic (x-ray) examination.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

5-[2-chloro-N-(2-hydroxyethyl)acetamido]-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodobenzene-1,3-dicarboxamide5-Amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamideN-DesMethyl IoMeprol5 - chloro-acetamido-N, N - bis (2,3 - dihydroxypropyl) -2,4,6 - triiodo-1 ,3. Phthalimido5-[[2-(Acetyloxy)acetyl]amino]-2,4,6-triiodo-1,3-benzenedicarbonyl Dichloride

Zugehörige Reaktionen

3
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 265750
HRID 265750als Produkt
Reaktionsgleichung von HRID 1358849
HRID 1358849als Produkt
Reaktionsgleichung von HRID 2395870
HRID 2395870als Produkt

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung